https://www.selleckchem.com/products/MLN8054.html
G-CSF use was not associated with a shorter duration of neutropenia (p=.313) and was associated with a higher rate of neutropenia relapse (p=.002) in adjusted analysis. G-CSF use was associated with a decreased risk of hospitalization (aIRR 0.25 (95%CI 0.12-0.53) p.001) but there was no association with incidence of bacterial infection or rejection within 90days of neutropenic episode. G-CSF use for neutropenia in pediatric kidney transplant recipients did not shorten the overall duration of neutropenia but was associated with lower
Like
Comment
Share
